Scott Dax

Chief Scientific Officer at CerSci Therapeutics

Dr. Scott L. Dax has over 25 years of experience guiding research & development at both large pharma houses and small biotechnology companies. His leadership roles span chemistry, drug discovery, pharmacology, technology and intellectual property. Scott is Chief Scientific Officer at CerSci Therapeutics (www.cersci.com) leading efforts to develop a new generation of non-opioids to treat acute post-surgical pain and chronic painful diabetic neuropathy. CT-044, a Reactive Species Decomposition Accelerant (RSDAx) is completing IND-enablement and will enter clinical trials in January 2019. CerSci is grateful to have received a direct-to-phase 2 SBIR award to develop CT-044, as well as a phase 1 SBIR to advance an AMPK activator program.

Scott is also a Project Director at BioMotiv, a mission-driven development company associated with The Harrington Project for Discovery & Development, a national initiative centered at University Hospitals Cleveland Medical Center. The company focus is accelerating breakthrough discoveries from research institutions into therapeutics for patients.

Previously, Scott served as Chief Technology Officer at Galleon Pharmaceuticals, where he discovered and designed breathing control modulators to combat respiratory depression caused by opioid therapy, without compromising analgesia. This work has also led to clinical candidates for the treatment of narcotic-induced respiratory depression and sleep apnea. Scott’s contributions led to venture capital investments totaling >$60M.  Scott was also a Research Fellow & Analgesics Research Team Leader at Johnson & Johnson. His team delivered multiple New Chemical Entities into Early Development, working in the areas of delta-selective and mixed mu / delta opioid agonists, (Transient Receptor Potential) TRPV1 and TRPM8 antagonists, mono-acylglycerol lipase inhibitors, N-type calcium channel blockers, NSAIDs (non-steroidal anti-inflammatory drugs), voltage-gated sodium channel blockers and differentiated tramadol and acetaminophen analogs. Prior to J&J, Scott held positions at DuPont-Merck and Hoffmann-LaRoche working in the area of infectious diseases.

Scott  is  inventor  of  over  100  issued  patents  worldwide  and  more  than  100  publications/presentations in peer-reviewed journal and professional societies. Scott earned his Masters and Doctorate degrees in chemistry at the University of Michigan and was an NIH post-doctoral awardee at the University of Wisconsin.

My Sessions

Lessons Learned from Successful Companies: Navigating Application and Commercialization

Coronado Room

During this session you will hear from a panel of individuals who have received NIH SBIR and/or STTR awards and are navigating the commercialization process. Take advantage of the tips shared by these panelists about their up-and-down experiences transitioning technologies from the laboratory to the market.